Roche Holding AG (LTS:0QOK)
CHF 263.05 -1.65 (-0.62%) Market Cap: 211.30 Bil Enterprise Value: 236.93 Bil PE Ratio: 19.78 PB Ratio: 7.21 GF Score: 86/100

Roche Holding AG Neurology Update Transcript

Mar 11, 2024 / 02:00PM GMT
Release Date Price: CHF240.2 (+1.37%)
Operator

Ladies and gentlemen, welcome to Roche virtual neurology investor event. My name is Henrik, and I'm the technical operator for today's call.

Kindly note that the webinar is being recorded. (Operator Instructions) One last remark: If you would like to follow the presented slides on your end as well, please feel free to go to roche.com/investors to download the presentation.

At this time, it's our pleasure to introduce you to Bruno Eschli, Head of Investor Relations.

Bruno, the stage is yours.

Bruno Eschli
Roche Holding AG - Head of IR

Thanks a lot, Henrik. And then can I have, please, the agenda slide, first?

So welcome to our first IR call in 2024, focusing on our neurology franchise and especially on the latest data which were presented at MDA a week ago and just over the weekend at AD/PD.

So let me quickly take you through the agenda. We have 3 speakers with us today: first, Paulo Fontoura, our global head of neuroscience, immunology, ophthalmology, cardiometabolic, infectious and rare diseases clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot